

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

A

UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under
37 C.F.R. 1.53(b))

Attorney Docket No.

1855.107004

First Named Inventor or
Application Identifier

Michael J. Briskin

Express Mail Label No.

EL 136578819 US

Title of
Invention

NOVEL ANTIBODIES AND LIGANDS FOR "BONZO" CHEMOKINE RECEPTOR

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:

Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

1. ☐ Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)

2. ☒ Specification [Total Pages 87]

(preferred arrangement set forth below)

- Descriptive title of the invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to microfiche Appendix
- Background of the Invention
- Summary of the Invention
- Brief Description of the Drawings
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

3. ☒ Drawing(s) (35 U.S.C. 113) [Total Sheets 40]

☒ Formal ☐ Informal

☐ Fig. of the Drawings for Publication ☐

4. ☒ Oath or Declaration/POA [Total Pages 3]

a. ☐ Newly executed (original or copy)

b. ☒ Copy from a prior application (37 C.F.R. 1.63(d))
(for continuation/divisional with Box 18 completed)

[NOTE Box 5 below]

i. ☐ DELETION OF INVENTOR(S)

Signed statement attached deleting
inventor(s) named in the prior
application, see 37 C.F.R. 1.63(d)(2)
and 1.33(b).

5. ☒ Incorporation By Reference (useable if Box 4b is checked)
The entire disclosure of the prior application, from which a
copy of the oath or declaration is supplied under Box 4b, is
considered as being part of the disclosure of the accompanying
application and is hereby incorporated by reference therein.

6. ☐ Microfiche Computer Program (Appendix)

7. ☒ Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)

a. ☐ Computer Readable Copy

b. ☒ Paper Copy (identical to computer copy)

7 Pages

c. ☒ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☐ Assignment Papers (cover sheet & documents)

☒ Assignee - Millennium Pharmaceuticals, Inc.
Cambridge, Massachusetts

9. ☐ 37 C.F.R. 3.73(b) Statement ☐ Power of Attorney
(when there is an assignee)

10. ☐ English Translation Document (if applicable)

11. ☒ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations

12. ☒ Preliminary Amendment

13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)

14. ☐ Small Entity Statement(s) ☐ Statement filed in prior application,
status still proper and desired

15. ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)

16. ☐ Nonpublication Request (check parent application)

17. ☒ Other: Request under 37 C.F.R. § 1.821(e), Statement
Under 37 C.F.R. § 1.806 and 1.808; Remarks Letter

18. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☒ Divisional ☐ Continuation-in-part (CIP)

of prior application No.: 09/449,437

Prior application information: Examiner: J. Roark

Group Art Unit: 1644

19. CORRESPONDENCE ADDRESS

NAME

Helen E. Wendler, Esq.

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

ADDRESS

Two Militia Drive

CITY

Lexington

STATE

MA

ZIP CODE

02421-4799

COUNTRY

USA

TELEPHONE

(781) 861-6240

FAX

(781) 861-9540

Signature

Robert H. Underwood

Date

August 27, 2001

Submitted by
Typed or Printed Name

Robert H. Underwood

Reg. Number

45,170


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Michael J. Briskin, Kristine E. Murphy, Alyson M. Wilbanks and Lijun Wu

Divisional of:

Application No.: 09/449,437
Filed: November 24, 1999

Title: NOVEL ANTIBODIES AND LIGANDS FOR "BONZO" CHEMOKINE RECEPTOR



STATEMENT UNDER 37 C.F.R. § 1.806 AND § 1.808

Box Patent Application
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


Pursuant to 37 C.F.R. § 1.806 and § 1.808 the undersigned states:

1. The above-referenced application contains reference to three biological deposits. Murine hybridomas 7F3 (also referred to as murine hybridoma LS212-7F3-8-7), 4A11 (also referred to as murine hybridoma LS212-4A11-30-8) and 7A2 (also referred to as murine hybridoma LS212-7A2-32-1) were deposited on November 24, 1999 at the American Type Culture Collection, 10801 University Boulevard, Manassas, VA, 20110-2209, in accordance with the terms of the Budapest Treaty under Accession Nos. PTA-990, PTA-991 and PTA-992, respectively.

2. Deposits PTA-990, PTA-991 and PTA-992 will be maintained in a public depository for the enforceable life of the patent which issues from the above-referenced application, a term of at least thirty years from the date of deposit or at least five years after the most recent request for the furnishing of a sample of the deposit is received by the depository, whichever is longer.
3. In accordance with 37 C.F.R. §1.808(a)(1), access to deposits PTA-990, PTA-991 and PTA-992 will be available during the pendency of the above-referenced application to one determined by the Commissioner to be entitled thereto under 37 C.F.R. §1.14 and 35 U.S.C. §122.
4. In accordance with 37 C.F.R. §1.808(a)(2), and except as permitted by 37 C.F.R. §1.808(b), all restrictions imposed by the depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of a patent on the above-referenced application.
5. The undersigned is an agent of record.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By 

Robert H. Underwood
Registration No. 45,170
Telephone (781) 861-6240
Facsimile (781) 861-9540

Lexington, Massachusetts 02421-4799

Dated: *August 27, 2001*